

82 mm x 162 mm

ANGINOX

Trimetazidine hydrochloride BP

Presentation

Anginox Tablet: Each film coated tablet contains Trimetazidine hydrochloride BP 20mg.

Indications

- ❖ Ischemic heart disease (angina pectoris, sequelae of infarction)
- ❖ Adjuvant symptomatic treatment of vertigo and tinnitus
- ❖ Adjuvant treatment of the decline visual acuity and visual field disturbances, presumably of vascular origin.

Dosage and administration

Adult: One tablet thrice daily after meal. No dosage adjustment is required in patients with impaired renal and hepatic function.

Child: Safety and efficacy have not been established with Trimetazidine.

Contraindications

Hypersensitivity to Trimetazidine hydrochloride.

Use in pregnancy and lactation

Pregnancy: Studies in animals have not demonstrated a teratogenic effect. However, in the absence of clinical data and for safety reasons, prescription should be avoided during pregnancy.

Nursing mothers: There is no information on the secretion of Trimetazidine into breast milk. However, breast-feeding should be discontinued if the use of Trimetazidine is considered essential.

Drug Interactions

No drug interactions have so far been reported.

Storage

Store at a temperature not exceeding 30°C. Protect from direct sunlight. Keep out of reach of children.

Shelf-life

Please refer to outer carton.

Commercial Pack

Anginox Tablet: Please refer to outer carton.

Manufactured By :

 **GENERAL**
Pharmaceuticals Ltd.
Talchela, Mouchak, Kalakoti, Gazipur, Bangladesh
www.generalpharma.com

GENERAL Pharmaceuticals Ltd.
ISO 9001:2000 Certified Company

